Current textbook knowledge holds that the structural scope of ribosomal biosynthesis is based exclusively on a-amino acid backbone topology. Here we report the genome-guided discovery of bacterial pathways that posttranslationally create b-amino acid-containing products. The transformation is widespread in bacteria and is catalyzed by an enzyme belonging to a previously uncharacterized radical S-adenosylmethionine family. We show that the b-amino acids result from an unusual protein splicing process involving backbone carbon-carbon bond cleavage and net excision of tyramine. The reaction can be used to incorporate diverse and multiple b-amino acids into genetically encoded precursors in Escherichia coli. In addition to enlarging the set of basic amino acid components, the excision generates keto functions that are useful as orthogonal reaction sites for chemical diversification.
O vercoming the structural limitations of ribosomal biosynthesis, which is based on a restricted set of amino acids, is important in biology and applied life sciences (1) (2) (3) (4) . Natural proteins and ribosomally produced peptides are diversified through posttranslational modifications that equip them with a wide range of added structural and functional features (1) . All known ribosomally generated biomolecules are based on a-amino acid backbone topologies. In synthetic biology, efforts have been made to incorporate non-a-amino acid residues into proteins by ribosome engineering or by tRNA misacylation. Although in vitro strategies have resulted in products containing a-hydroxy or b-amino acids (5-9), we know of only a single in vivo case, which used mutated ribosomes to incorporate b 3 -Phe-based units (10) . We recently reported the discovery of radical S-adenosylmethionine (rSAM) enzymes that irreversibly introduce multiple D-amino acids into ribosomally synthesized and posttranslationally modified peptides (RiPPs) (11) (12) (13) (14) . These enzymes act on small precursor proteins containing either a nitrile hydratase-like (also termed proteusin) or a Nif11-like N-terminal leader and a variable C-terminal core region. During biosynthesis, the core is modified and proteolytically released from the leader. Although the encoding biosynthetic gene clusters are widespread in bacteria (15) , the only proteusins that have been characterized to date are the cytotoxic, pore-forming polytheonamides (11, (16) (17) (18) , which are the most extensively modified known peptides and contain numerous D-amino acids introduced by a rSAM epimerase (11, 14) .
In a broader analysis of such RiPP clusters, genes encoding an orphan rSAM family (TIGR04103, rSAM_nif11_3) attracted our attention owing to their consistent colocalization with Nif11 precursor genes. These rSAMs contain a C-terminal region with homology to SPASM domains present in various peptide-modifying rSAM enzymes (19) . One homolog, here termed PlpX, is encoded in the orphan plp locus from Pleurocapsa sp. PCC 7319. The locus contains one proteusin and two Nif11 precursor genes, as well as the previously characterized rSAM epimerase PlpD (Fig. 1A ) (12, 13) . To assign function to the remaining genes in the plp cluster, we studied the activity of PlpX. We coexpressed the gene with either of the two Nif11 precursor genes plpA2 and plpA3, which are located directly upstream and encode precursors with predicted cores of 25 and 23 amino acids, respectively (Fig. 1B) . Both precursor genes were modified to produce N-terminally His 6 -tagged proteins carrying a factor Xa (Fx) cleavage site at the leader-core interface. After coexpression with plpX in Escherichia coli BL21(DE3), Niaffinity purification, and cleavage with trypsin, the core peptides 1 and 2 of His 6 -PlpA2-Fx and His 6 -PlpA3-Fx, respectively, lacked detectable modifications ( Fig. 2A) . Closer analysis of the plp locus (Fig. 1A) , however, revealed an unannotated small open reading frame, named plpY, located downstream of plpX, an architecture that we also detected in other clusters encoding PlpX homologs (figs. S1 and S2 and table S1). PlpY has weak similarity to PqqD from pyrroloquinoline quinone biosynthesis (20) and to the RiPP recognition element domains that occur in various modifying enzymes and mediate precursor binding (21) (fig. S3 ). When plpY was coexpressed with plpX and plpA2 or plpA3, the liquid chromatographymass spectrometry (LC-MS) chromatograms contained two additional broad peaks ( Fig. 2A ) that partially overlapped with unmodified 1 (products 3 and 4) and 2 (products 5 and 6). Tandem mass spectrometry (MS/MS) experiments (Fig. 2B ) revealed a mass difference consistent with C 8 H 9 NO loss in PlpA2 (diastereomers 3 and 4) and PlpA3 (diastereomers 5 and 6), which was mapped to core regions carrying tyrosine residues (Tyr 21 and Tyr 6 , respectively; numbering relates to core position). For detailed product characterization, simultaneous digestion of the His 6 -PlpA3-Fx product with trypsin and chymotrypsin cleanly provided a core fragment (Ala 1 to Trp
12
) composed of two diastereomers (7 and 8; Fig. 2C ), which were separated by means of high-performance LC. Nuclear magnetic resonance (NMR) analysis (figs. S4 to S15 and tables S3 and S4) revealed heteronuclear two-and three-bond correlations that suggest an a-keto-b 3 -Met moiety present in both diastereomers. Specifically, we observed cross peaks to the newly formed ketone and amide carbonyls with characteristic chemical shifts of d = 196 and 165 parts per million (figs. S9 and S15), respectively, similar to those of other a-keto-b 3 -Met-containing peptides (22) . Attempts to obtain an enzymatic product enriched in one diastereomer were unsuccessful, in line with the tendency of a-ketoamides to tautomerize at physiological pH (23) .
Using His 6 -PlpA3-Fx, we next investigated the origin of the b-amino acid moiety by feeding various 13 C-labeled amino acids to expression cultures. data confirm that PlpX catalyzes an unusual reaction involving tyramine excision from the backbone and reconnection of the remaining protein sections to generate b-amino acids (Fig. 2, C and  D) . b-Amino acids with or without a-keto groups are only known for nonribosomal and polyketide pathways ( fig. S20 ), where they are integrated by direct incorporation of b-residues, amination of polyketide moieties (24) , or by as-yet uncharacterized net C1 extension mechanisms (25, 26) .
C-C bond cleavage is known for various rSAM enzymes acting on free amino acids (27-33)-for example, the hydrogenase maturation protein HydG cleaving Tyr to p-cresol, CO, and CN -(30). These lyases are only distantly related (<15% amino acid identity) to PlpX and do not contain a SPASM domain. We hypothesized that the PlpXY mechanism may involve formation of p-cresol, as for HydG. However, many attempts to detect p-cresol or structural variants with or without nitrogen in in vivo coexpressions were unsuccessful. In RiPP biosynthesis, rSAM and SPASM domain-containing proteins catalyze diverse reactions (34) . In protein alignment and network analyses of PlpX and other SPASM domain proteins, MftC, catalyzing a C-terminal oxidative decarboxylation and Tyr-Val C-C cross-link event (35) , was the closest characterized homolog (figs. S21 and S22).
To obtain insights into the prevalence and distribution of this modification, we analyzed bacterial (meta)genomes deposited in GenBank, as well as 93 newly sequenced cyanobacteria from the Pasteur Culture Collection, for genes that associate with the same TIGRFAM family as the splicase PlpX. We detected 53 positives in 436 phylogenetically diverse cyanobacteria, almost all of them neighboring nif11-and plpY-type genes (figs. S23 and S24 and table S5). All precursors comprise between one and three Tyr residues that are part of conserved "XYG" motifs also present in the splice sites of PlpA2 and PlpA3. Additional members of TIGRFAM rSAM_nif11_3 also occur in various proteobacteria and Frankia spp. actinomycetes (table S5) . Each splicase gene was consistently flanked by a small gene encoding YG peptides. Notable examples are genes from Thiothrix spp. for proteins with up to five YG copies. Neither Nif11-type leaders nor PlpY homologs were identified in these noncyanobacterial systems. We detected 27 further rSAM gene candidates in the TARA Ocean metagenomic data set (36) , for which six contigs were long enough to reveal adjacent genes for YG peptides (table  S5) . These data suggest that various prokaryotes are able to generate b-amino acid-containing products. To test whether multiple YG sites direct several splicing events in one precursor, we coproduced His 6 -PcpA bearing three YG motifs (9; Fig. 1B ) from the thermophile Pleurocapsa sp. PCC 7327 (Fig. 1A and fig. S24 ) with its splicase gene partners pcpX and pcpY. Proteolysis and LC-MS analysis (figs. S25 and S26) revealed two modifications at the C-terminal YG motifs (Tyr 15 and Tyr 56 ) to give product 10 ( Fig. 2C and figs. S27 to S29), demonstrating that a single splicase can catalyze excisions at multiple sites in one protein. The fate of this moiety and the structure of the natural products from these gene clusters remain cryptic and are under investigation in our laboratory.
The introduction of a-keto-b-amino acids into gene-encoded precursors has considerable potential for applications in drug discovery, chemical biology, and synthetic biology, which we started to explore in a series of experiments. Eight different residues (where X is Ala, Met, His, Leu, Ile, Cys, Phe, or Lys) are part of the currently known cyanobacterial XYG motifs, and six further residues (where X is Gly, Val, Ser, Asp, Glu, or Arg) occur in other bacteria (table S5) . To evaluate the potential of PlpX to generate diverse b-residues, we constructed ten Met substitution mutants at the MYG site of His 6 -PlpA3-Fx (Fig. 3A) . Of these, seven (Gly, Val, Leu, Ser, Ala, and the not yet naturally observed Pro and Gln) were converted, whereas Phe, Glu, and Arg mutants were not at all or only poorly accepted (figs. S30 to S39 and table S6). Various insertion, deletion, or substitution mutations surrounding the XYG motif were generally tolerated (Fig. 3B and figs. S40 to S44), but mutations within YG abolished splicing (Fig. 3B, figs. S45 and S46, and table S6). We also generated His 6 -PlpA3-Fx truncation variants (Fig. 3C , figs. S47 to S52, and table S6) to identify a minimal core sequence converted by PlpXY. These studies defined an 11-residue sequence (11) that is accepted, suggesting opportunities to introduce a-ketoamides into peptides and proteins in a motif-based fashion. During these mutational analyses, we also gained initial insights into the nature of the excision reaction. We noticed that one of the point mutant coexpressions (His 6 -PlpA3-Fx-4A5 plus PlpXY) yielded truncated C-terminal Met5-amide as by-product (Fig. 3D and fig. S53 ), which was not observed from a wild-type precursor. This shunt product might arises from inefficient conversion of an imine intermediate (e.g., a dehydroglycine moiety) that might form after initial radical cleavage of the tyrosine side chain, analogous to HydG catalysis ( fig. S54) (30) .
Two strategies to genetically incorporate reactive carbonyls use evolved tRNA-aminoacyl tRNA synthetase pairs (37) and the aldehyde chemical tag (38) . To test the potential of PlpX for orthogonal labeling, the His 6 -PlpA3-Fx ketoamide was converted in vitro to the corresponding oxime in the presence of methoxyamine ( fig. S55 ). In addition, the ketoamide was conjugated to fluorescein-5-thiosemicarbazide (12) under mild conditions to give the corresponding fluorescent product 13 ( Fig. 4A and fig. S56 ).
Natural (nonribosomal; fig. S20 ) and synthetic products containing a-ketoamide moieties show diverse bioactivities (39) . Of particular medical importance is the inhibition of cysteine and serine proteases by reversible binding to the keto group. Industrial screening of synthetic ketoamide peptide libraries identified CVS 4453 (14) as a hepatitis C virus protease inhibitor lead. Further optimization provided boceprevir 15 (Fig. 4B) , an approved drug for the treatment of chronic hepatitis C infections (40) (41) (42) . We generated a core related to 14 by replacing the first five residues within His 6 -PlpA3-Fx to give engineered precursor 16. This precursor contains six non-native residues N-terminally flanking the YG motif. Coproduction with PlpXY provided the corresponding ketoamide 17 with a conversion comparable to that of His 6 -PlpA3-Fx ( fig. S57 ). This result suggests the potential of using synthetic biology platforms to access and screen genetically encoded ketoamide pharmacophore libraries for drug discovery.
We demonstrate a naturally occurring splicing reaction that introduces diverse and multiple aketo-b-amino acids into proteins. This work opens multiple avenues for applications in chemistry and biology and highlights how bioinformatic analyses can streamline experiments to discover pathways and transformations that change the way we view fundamental biology. 
